The study demonstrates that the CRISPR nuclease Cas12a2 can selectively eliminate yeast and human cells based on their RNA expression profiles, effectively inducing cell death through RNA-triggered DNA damage. This approach expands the potential applications of CRISPR technology in targeted therapies for diseases, including cancer, by enabling precise removal of cells with specific genetic characteristics.
The recent discovery of Cas12a2, a type V CRISPR nuclease, marks a significant advancement in gene-editing technology, enabling RNA-triggered programmable cell elimination in eukaryotic cells, including yeast and human cells. This breakthrough allows for targeted cell death by inducing double-stranded DNA breaks upon recognition of specific RNA transcripts, without off-target effects. This expands the CRISPR toolbox, providing a novel method to selectively eradicate cells based on their transcriptional profiles, which could be pivotal in precision medicine, targeting conditions like oncogenic mutations in KRAS or human papillomavirus infections.